To read this content please select one of the options below:

Purinex, Inc.

Publication date: 20 January 2017

Abstract

In June 2004 Purinex, Inc., a pharmaceutical company with several clinically and commercially promising drugs in development, expected to secure a partnership with a major pharmaceutical company sometime in the next four to 12 months. That partnership, if secured, would enable Purinex to develop one of its leading compounds as a drug. The company, however, had no sales or earnings and only 11 months of cash on hand. The student must assess whether the company should attempt to secure financing now or wait until it consummated a partnership deal. The tasks for the student include evaluating the probabilities that collaboration with a pharmaceutical company would actually happen; determining whether the company stay above water until such occurred; and analyzing the other risks to the company under these circumstances.

Keywords

Citation

Bruner, R.F. and Carr, S. (2017), "Purinex, Inc.", . https://doi.org/10.1108/case.darden.2016.000244

Publisher

:

University of Virginia Darden School Foundation

Copyright © 2005 by the University of Virginia Darden School Foundation, Charlottesville, VA. All rights reserved.

Related articles